Less Is More
George F. Sawaya, MD; Erinn Sanstead, MPH; Fernando Alarid-Escudero, PhD; et al.
free access
has audio
JAMA Intern Med. 2019;179(7):867-878. doi:10.1001/jamainternmed.2019.0299
This cost-effectiveness analysis estimates the quality of life and economic outcomes associated with 12 cervical cancer screening strategies among women aged 21 to 65 years.
-
Podcast:
Estimated Quality of Life and Economic Outcomes Associated With Cervical Cancer Screening
Nicolas Wentzensen, MD, PhD, MS; Megan A. Clarke, PhD; Renee Bremer, MS; et al.
open access
JAMA Intern Med. 2019;179(7):881-888. doi:10.1001/jamainternmed.2019.0306
This cohort study evaluates the performance of the p16/Ki-67 dual stain and human papillomavirus (HPV) 16/18 genotyping for the triage of women with HPV infection.
XinQi Dong, MD, MPH; Bei Wang, MPH
free access
JAMA Intern Med. 2019;179(7):889-896. doi:10.1001/jamainternmed.2019.0313
This cross-sectional study of 3157 US Chinese older adults examines the associations of child maltreatment and intimate partner violence with elder abuse.
Samia Mora, MD, MHS; C. Lan Chang, PhD; M. Vinayaga Moorthy, PhD; et al.
free access
JAMA Intern Med. 2019;179(7):898-905. doi:10.1001/jamainternmed.2019.0392
This secondary analysis of a randomized clinical trial compares the association of nonfasting vs fasting lipid levels with coronary and vascular outcomes and assesses differences in calculated risk among participants undergoing both measurements.
Bishal Gyawali, MD, PhD; Spencer Phillips Hey, PhD; Aaron S. Kesselheim, MD, JD, MPH
free access
JAMA Intern Med. 2019;179(7):906-913. doi:10.1001/jamainternmed.2019.0462
This study assesses the end points used to verify benefit in confirmatory trials of cancer drugs approved via the FDA鈥檚 accelerated approval pathway and updates the status of indications for which confirmatory trials were ongoing during the initial analysis of accelerated approval.
Emerson Y. Chen, MD; Vikram Raghunathan, MD; Vinay Prasad, MD, MPH
free access
JAMA Intern Med. 2019;179(7):915-921. doi:10.1001/jamainternmed.2019.0583
This study examines the US Food and Drug Administration鈥檚 use of response rates as surrogate end points for approval of cancer drugs.
Derek A. Haas, MBA; Xiaoran Zhang, MA; Robert S. Kaplan, PhD; et al.
free access
JAMA Intern Med. 2019;179(7):924-931. doi:10.1001/jamainternmed.2019.0480
This population-based study examines the changes in economic and clinical outcomes after institution of the Comprehensive Care for Joint Replacement bundled payment program by the Centers for Medicare & Medicaid Services.
Thomas W. Ferguson, MSc; Amit X. Garg, MD; Manish M. Sood, MD; et al.
free access
JAMA Intern Med. 2019;179(7):934-941. doi:10.1001/jamainternmed.2019.0489
This study examines the implications of the Initiating Dialysis Early and Late randomized clinical trial findings for the dialysis initiation decision and other interventions for patients who need long-term dialysis.
Sean J. Barbour, MD, MSc; Rosanna Coppo, MD, FERA; Hong Zhang, MD, PhD; et al.
free access
JAMA Intern Med. 2019;179(7):942-952. doi:10.1001/jamainternmed.2019.0600
This modeling study uses international, multi-ethnic derivation and validation cohorts of patients with biopsy-proven IgA nephropathy to evaluate a risk-prediction tool for 50% decline in kidney function or end-stage renal disease.
Peiqi Wang, MD, MPH; Susan M. Hutfless, PhD; Eun J. Shin, MD; et al.
free access
JAMA Intern Med. 2019;179(7):953-963. doi:10.1001/jamainternmed.2018.8766
This cohort study uses US Medicare claims to estimate the rate of different-day upper and lower endoscopic procedures in 3 types of outpatient settings and investigate the factors associated with the performance of these procedures on different days.